Darnytsia Launches 13 New Medicines in 2024

In 2024, Darnytsia Pharmaceutical Company introduced 13 new medicines to the market.

These include antimicrobial medicines for systemic use, such as treatments for community-acquired pneumonia, pain relief medications, nonsteroidal anti-inflammatory and antirheumatic medicines, antidepressants, corticosteroids, allergy treatments, medicines for throat and oral conditions, and other pharmaceuticals.

Darnytsia’s portfolio today features both original and generic medicines.

It is worth noting that generic medicines contain the same active ingredients in the same quantities as original innovative drugs and match them in efficacy and safety, as confirmed by research conducted in accordance with modern global standards.

Darnytsia offers a wide range of effective medicines, focusing on health issues most relevant to Ukrainians. These include cardiovascular and neurological diseases, as well as pain management.

By 2029, Darnytsia plans to launch 62 new brands. Of these, 43 will be in-house developments, while 19 will be produced under licensing agreements.

“As a national pharmaceutical manufacturer, we understand the medicines Ukrainians need today. We analyse factors influencing the prevalence of specific diseases in Ukraine and promptly offer effective and safe medicines to address them. Each new medicine brand launched reflects our progress, enabling us to align with global medical standards, strengthen the nation’s health, and bolster our pharmaceutical independence,” said Inna Deniak, Development Director at Darnytsia Pharmaceutical Company.